Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 92

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic106Crohn's disease94Colorectal cancer90Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma40Adenocarcinoma pancreas36Pancreatic carcinoma metastatic35Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome31Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Colorectal adenocarcinoma16Endometrial cancer16+450

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Atypical haemolytic uraemic syndrome+1

Not recruiting

Study on Ravulizumab for Children with Paroxysmal Nocturnal Hemoglobinuria or Atypical Hemolytic Uremic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Oesophageal adenocarcinoma+1

Not recruiting

Study on SOT102 for Patients with Advanced Gastric and Pancreatic Cancer, Alone or with Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:SOTIO Biotech a.s.

Oropharyngeal cancer

Not recruiting

Study on Swallowing and Quality of Life in Advanced Head and Neck Cancer Patients Using Cisplatin and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barium Sulfate
  • Sponsor:Institut Jules Bordet

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Constipation

Not recruiting

Study on Linaclotide for Treating Functional Constipation in Children Aged 2 to 5 Years

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Linaclotide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Gastrointestinal stromal tumour

Not recruiting

Study of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Microsatellite instability cancer+1

Not recruiting

Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Rectal cancer

Not recruiting

Study Comparing Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin to Standard Treatment for Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Region Sjaelland

Pancreatic carcinoma+1

Not recruiting

Study on the Safety and Effects of Nivolumab, Ipilimumab, Gemcitabine, and Paclitaxel for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Rigshospitalet

Pancreatic carcinoma

Not recruiting

Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Crohn's disease

Not recruiting

Study on Local Injection of Mesenchymal Stem Cells for Patients with Refractory Crohn's Disease Lesions

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Bone Marrow-Derived Mesenchymal Adult Stromal Cells, Ex-Vivo Expanded
  • Sponsor:CHU De Liege

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil207 clinical trialsOxaliplatin197 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate69 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate53 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.